Patents by Inventor John M. McPherson
John M. McPherson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180104180Abstract: A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminolycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures.Type: ApplicationFiled: May 23, 2017Publication date: April 19, 2018Inventors: Kuber T. Sampath, Michael Philbrook, Aviva Shiedlin, John M. McPherson
-
Publication number: 20170326203Abstract: Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-? and/or another agent that promotes expansion of regulatory T cells. In certain aspects, the disclosed process results in improved kidney function and survival rates.Type: ApplicationFiled: August 2, 2017Publication date: November 16, 2017Applicant: GENZYME CORPORATIONInventors: Johanne Kaplan, John M. McPherson
-
Publication number: 20170165360Abstract: Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-? and/or another agent that promotes expansion of regulatory T cells. In certain aspects, the disclosed process results in improved kidney function and survival rates.Type: ApplicationFiled: November 19, 2012Publication date: June 15, 2017Inventors: Johanne KAPLAN, John M. McPHERSON
-
Publication number: 20150044164Abstract: Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-? and/or another agent that promotes expansion of regulatory T cells. In certain aspects, the disclosed process results in improved kidney function and survival rates.Type: ApplicationFiled: November 19, 2012Publication date: February 12, 2015Applicant: GENZYME CORPORATIONInventors: Johanne KAPLAN, John M. McPHERSON
-
Publication number: 20140271471Abstract: A non-invasive injectable composition that contains type I collagen, an osteogenic growth factor (OSF), such as a bone morphogenetic protein and a reverse thermo-sensitive biodegradable polymer such as Poloxamer 407 in an aqueous vehicle. The formulation can be administered non-invasively, e.g., by injection, thus circumventing limitations of many currently marketed bone-inducing products. The injectable osteogenic formulation effectively induces bone formation at the desired locale. This injectable suspension could be used with bioresorbable bone mineral composites (e.g., Hydroxyapatite, Tri-calcium phosphate) and/or glycosaminoglycans (e.g., Hyaluronic acid, Heparin sulfate) to mold as putty and/slab as bone graft substitute implants to induce new bone formation in fracture healing and spine fusion procedures.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Genzyme CorporationInventors: Kuber T. Sampath, Michael Philbrook, Aviva Shiedlin, John M. McPherson
-
Publication number: 20130344092Abstract: Novel uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-? are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases.Type: ApplicationFiled: August 28, 2013Publication date: December 26, 2013Applicants: The Brigham and Women's Hospital, Inc., Genzyme CorporationInventors: Nader Najafian, Mohamed H. Sayegh, Melanie Ruzek, Srinivas Shankara, John Williams, Johanne Kaplan, John M. McPherson
-
Patent number: 8071336Abstract: Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.Type: GrantFiled: February 12, 2010Date of Patent: December 6, 2011Assignee: Genzyme CorporationInventors: John M. McPherson, Tim Edmunds, Qun Zhou
-
Publication number: 20100184145Abstract: Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.Type: ApplicationFiled: February 12, 2010Publication date: July 22, 2010Inventors: John M. McPherson, Tim Edmunds, Qun Zhou
-
Publication number: 20100183541Abstract: Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-? and/or another agent that promotes expansion of regulatory T cells. In certain aspects, the disclosed process results in improved kidney function and survival rates.Type: ApplicationFiled: September 30, 2008Publication date: July 22, 2010Inventors: Johanne M. Kaplan, John M. McPherson
-
Patent number: 7700321Abstract: Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.Type: GrantFiled: October 20, 2006Date of Patent: April 20, 2010Assignee: Genzyme CorporationInventors: John M. McPherson, Tim Edmunds, Qun Zhou
-
Publication number: 20100034782Abstract: Uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-beta are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases.Type: ApplicationFiled: May 31, 2007Publication date: February 11, 2010Inventors: Nader Najafian, Mohamed H. Sayegh, Melanie Ruzek, Srinivas Shankara, John Williams, Johanne Kaplan, John M. McPherson
-
Publication number: 20090075887Abstract: Methods, kits and compositions are disclosed that include a non-naturally occurring kallikrein inhibitor and optionally a viscosupplement for the treatment of joint pathology.Type: ApplicationFiled: August 20, 2008Publication date: March 19, 2009Applicant: GENZYME CORPORATIONInventor: JOHN M. MCPHERSON
-
Patent number: 6150163Abstract: One object of the present invention is based upon the development and use of a serum-free defined cell culture medium comprising a supplement mixture, a component mixture, a vitamin mixture, an inorganic salt mixture and amino acid mixture that avoids the problems inherent in the use of serum. In particular, the defined medium is useful in culturing fibroblasts, especially chondrocytes. Another object of the present invention is to claim a method of enhancing the differentiation of chondrocytes and enhancing the synthesis of a cartilage specific matrix using tumor growth factor beta (TGF-.beta.). Another object of the present invention is to claim a method of enhancing the differentiation of chondrocytes using the combination of TGF-.beta.and IGF.Type: GrantFiled: January 13, 1999Date of Patent: November 21, 2000Assignee: Genzyme CorporationInventors: John M. McPherson, Peter C. Yaeger, Marie E. Brown, James G. Hanlon, Francois Binette
-
Patent number: 5219576Abstract: Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and a pore population in which at least about 80% of the pores have an average pore size of 35 to 250 microns. The implants are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The wound healing matrix also serves as an effective sustained delivery system for bioactive agents.Type: GrantFiled: December 3, 1991Date of Patent: June 15, 1993Assignee: Collagen CorporationInventors: George H. Chu, Yasushi Ogawa, John M. McPherson, George Ksander, Bruce Pratt, Diana Hendricks, Hugh McMullin
-
Patent number: 5110604Abstract: Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and a pore population in which at least about 80% of the pores have an average pore size of 35 to 250 microns. The implants are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The wound healing matrix also serves as an effective sustained delivery system for bioactive agents.Type: GrantFiled: December 19, 1990Date of Patent: May 5, 1992Assignee: Collagen CorporationInventors: George H. Chu, Yasushi Ogawa, John M. McPherson, George Ksander, Bruce Pratt, Diana Hendricks, Hugh McMullin
-
Patent number: 5024841Abstract: Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm.sup.3 and a pore population in which at least about 80% of the pores have an average pore size of 35 to 250 microns. The implants are capable of promoting connective tissue deposition, angiogenesis, reepithelialization, and fibroplasia. The wound healing matrix also serves as an effective sustained delivery system for bioactive agents.Type: GrantFiled: June 30, 1988Date of Patent: June 18, 1991Assignee: Collagen CorporationInventors: George H. Chu, Yasushi Ogawa, John M. McPherson, George Ksander, Bruce Pratt, Diana Hendricks, Hugh McMullin
-
Patent number: 4816442Abstract: Polypeptides called cartilage-inducing factors (CIFs) that are found in bone and have heretofore been identified as having in vitro cartilage-inducing activity. TGF-.beta. activity, and anti-inflammatory activity have now been found to possess potent oncostatic activity. The CIFs showed oncostatic activity on human and animal tumors, including carcinomas, adenocarcinomas, lymphomas, and melanomas.Type: GrantFiled: November 7, 1986Date of Patent: March 28, 1989Assignee: Collagen CorporationInventors: John M. McPherson, Danile R. Twardzik, George J. Todaro, Karl A. Piez, Jane E. Ranchalis
-
Patent number: 4789663Abstract: A method of repairing bone defects by use of suspensions containing purified atelopeptide, reconstituted, fibrillar skin collagen or bone collagen powder or mixtures thereof is disclosed. The suspensions provide matrices for conductive growth of bone into the defect. The skin collagen may also be lyophilized and used in the form of mats.Type: GrantFiled: July 5, 1985Date of Patent: December 6, 1988Assignee: Collagen CorporationInventors: Donald G. Wallace, Thomas L. Smestad, John M. McPherson, Karl A. Piez, Saeid Seyedin, Rosa Armstrong
-
Patent number: 4760131Abstract: A soft tissue wound healing composition comprising an aqueous mixture of fibrillar collagen, heparin, and undegranulated platelets or platelet releasate. The composition is applied topically to the wound site in conjunction with means to keep it at the site and hydrated or in the form of an occlusive dressing.Type: GrantFiled: June 23, 1986Date of Patent: July 26, 1988Assignee: Collagen CorporationInventors: John S. Sundsmo, George A. Ksander, John M. McPherson